Join us in-person for the 2025 DTRF "Together We Will" Weekend in Chicago from Sept. 12-13! - Register Today

The Desmoid Tumor Research Foundation

March 2021

MRI T1 Contrast-Enhanced Signal Intensity Is a Prognostic Indicator of Imatinib Therapy in Desmoid-Type Fibromatosis [Full Article]

Author Information

Zhu HC(1), Xu SX(2), Li XT(1), Guan Z(1), Li S(3), Sun YS(1).

(1)Dept Radiology, Peking Univ Cancer Hospital, Beijing, China.(2)Dept Plastic Surgery No.6, Plastic Surgery Hospital, Beijing, China.(3)Dept Bone & Soft Tissue Tumors, Peking Univ Cancer Hospital, Beijing, China.

Publication

Front Oncol

Summary

To investigate the efficiency of pre-therapy magnetic resonance imaging (MRI) features in predicting the prognosis of desmoid-type fibromatosis patients treated with imatinib. A total of 38 desmoid-type fibromatosis patients treated with imatinib were collected in this retrospective study. The high signal intensity on pre-therapy MRI was evaluated on axial T2 and T1 contrast-enhanced sequences with fat suppression. Hyperintense T1 contrast enhancement (CE) proportion (? 75%) was identified as an independent predictor for PFS. Patients with hyperintense T1 CE proportion <75% demonstrated no progression, while patients with hyperintense T1 CE proportion ?75% demonstrated a progression rate of 78.4%. Hyperintense T1 CE proportion in the tumor is a potential predictor of disease progression in patients with desmoid-type fibromatosis treated with imatinib. Hyperintense T1 CE proportion <75% indicates progression-free during treatment.

View Abstract